Benzinga | Feb 4, 2021 06:49AM EST

Annovis Bio Receives European Patent For Method Of Treating Acute Nerve And Brain Insults

Berwyn, Pennsylvania--(Newsfile Corp. - February 4, 2021) - Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the European Patent Office (EPO) granted the Company's patent for a method of treating acute nerve and brain injuries by administering ANVS405 after the injury.